Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

65.13USD
22 Sep 2017
Change (% chg)

$-0.47 (-0.72%)
Prev Close
$65.60
Open
$65.52
Day's High
$65.60
Day's Low
$65.07
Volume
3,032,257
Avg. Vol
2,826,073
52-wk High
$66.80
52-wk Low
$58.29

Select another date:

Fri, Sep 22 2017

BRIEF-Merck says FDA approves Keytruda(pembrolizumab) for previously treated patients

* Fda approves Merck’s keytruda® (pembrolizumab) for previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express pd-l1 (cps greater than or equal to 1)

BRIEF-Merck says Isentress HD now available in Canada

* Now available in Canada: Isentress HD (raltegravir), a new once-daily option, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in appropriate patients

BRIEF-Merck announces findings from phase 3 study of KEYTRUDA

* Merck announces findings from phase 3 study of KEYTRUDA (pembrolizumab), compared to standard of care, in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

Merck & Co snaps up three year-old German biotech firm for up to $550 million

FRANKFURT U.S. pharma group Merck & Co has acquired 3-1/2 year old German biotech start-up Rigontec for up to 464 million euros ($554 million), adding a new approach to its development of drugs that spur the immune system to attack tumors.

Merck & Co snaps up 3 yr-old German biotech firm for up to $550 mln

FRANKFURT, Sept 6 U.S. pharma group Merck & Co has acquired 3-1/2 year old German biotech start-up Rigontec for up to 464 million euros ($554 million), adding a new approach to its development of drugs that spur the immune system to attack tumours.

BRIEF-European Commission approves Merck’S KEYTRUDA (pembrolizumab)

* European Commission approves Merck’s KEYTRUDA (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

BRIEF-Merck announces results of REVEAL outcomes study of Anacetrapib

* Merck announces results of REVEAL outcomes study of Anacetrapib, investigational medicine for cardiovascular disease

Merck cholesterol drug cuts heart risk by 9 pct in study

Aug 29 A large study of Merck & Co Inc's experimental cholesterol drug anacetrapib found that it cut the risk of heart attack and death by a modest 9 percent, which could be due to its affect on bad LDL cholesterol, researchers said on Tuesday.

FDA expands use of AstraZeneca/Merck ovarian cancer drug

The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.

UPDATE 1-FDA expands use of AstraZeneca/Merck ovarian cancer drug

Aug 17 The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.

Select another date: